Sorrento CEO to Present at Upcoming Investor Conferences
November 12 2019 - 7:05AM
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced
today that Dr. Henry Ji, Chairman and CEO, will participate in
upcoming investor conferences in the 4th quarter 2019. Dr. Ji will
provide a corporate overview and business update focusing on the
clinical pipeline progress for Sorrento Therapeutics
immuno-oncology and pain programs.
Stifel 2019 Healthcare Conference
Date: Wednesday, November 20,
2019 Presenter: Dr. Henry Ji
Time: 9:45 AM Eastern Time
Location: Lotte New York Palace Hotel, NY
Evercore ISI 2nd Annual HealthCONx
Conference
Date: Tuesday, December 3,
2019 Presenter: Dr. Henry Ji
Time: 12:30 PM Eastern Time
Location: Four Seasons Hotel, Boston, MA
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to turn
malignant cancers into manageable and possibly curable diseases.
Sorrento's multimodal multipronged approach to fighting cancer is
made possible by its extensive immuno-oncology platforms, including
key assets such as fully human antibodies (“G-MAB™ library”),
antibody-drug conjugates (“ADC”) as well CAR-T and oncolytic virus
(“Seprehvir®”).
Sorrento's commitment to life-enhancing therapies for cancer
patients is also demonstrated by our effort to advance a
first-in-class (TRPV1 agonist) RTX and ZTlido®. RTX is completing a
phase IB trial in terminal cancer patients. ZTlido® was approved by
US FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc. under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward looking
statements include statements regarding the developments of and
prospects for Sorrento's and its subsidiaries’ and affiliates’
products and technologies, expected research and development and
clinical trials. Risks and uncertainties that could cause our
actual results to differ materially and adversely from those
expressed in our forward-looking statements, include, but are not
limited to: risks related to Sorrento's, its subsidiaries',
affiliates’ and partners’ technologies and prospects; clinical
development risks, including risks in the progress, timing, cost,
and results of clinical trials and product development programs;
risk of difficulties or delays in obtaining regulatory approvals;
risks that clinical study results may not meet any or all endpoints
of a clinical study and that any data generated from such studies
may not support a regulatory submission or approval; risks related
to seeking regulatory approvals and conducting clinical trials;
risks of supplying drug product; risks related to leveraging the
expertise of its employees, subsidiaries, affiliates and partners
to assist the company in the execution of its strategies; risks
related to Sorrento’s debt obligations; and other matters
that are described in Sorrento's Annual Report on Form 10-K for the
year ended December 31, 2018, and subsequent Quarterly Reports on
Form 10-Q filed with the Securities and Exchange Commission,
including the risk factors set forth in those filings. Investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release and we
undertake no obligation to update any forward-looking statement in
this press release except as required by law.
Media and Investor Relations
Contact: Alexis Nahama, DVM (SVP Corporate Development)
Telephone: 1.858.203.4120
Email: mediarelations@sorrentotherapeutics.com
ZTlido® and G-MAB™ are trademarks owned by Scilex
Pharmaceuticals Inc. and Sorrento, respectively.
Seprehvir®, is a registered trademark of Virttu Biologics
Limited, a wholly-owned subsidiary of TNK Therapeutics, Inc. and
part of the group of companies owned by Sorrento Therapeutics,
Inc.
All other trademarks are the property of their respective
owners.
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024